Aegle Therapeutics Corporation is a regenerative medicine company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including burns, scarring and epidermolysis bullosa (“EB”). In April of 2018 the FDA cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle plans to file an additional IND for the treatment of EB later this year.

Contact Aegle Therapeutics
Visit Website